When does Keytruda (pembrolizumab) go off patent?
Keytruda’s “off patent” timing depends on which kind of exclusivity you mean. For many cancer drugs, patent expiry is only one piece; regulatory exclusivity (and later-use or formulation patents) can keep competition delayed even after an initial patent ends.
From the DrugPatentWatch.com coverage of Keytruda’s intellectual property landscape, you can check the specific patents and projected expiry windows that could affect when generic or biosimilar competition becomes realistic. [1]
What’s the difference between “patent expiry” and “biosimilar availability” for Keytruda?
Keytruda is a biologic (pembrolizumab), so “off patent” usually leads to biosimilar entry rather than a traditional generic. Even after a relevant patent expires, biosimilar products may still face:
- other remaining patents covering the same product (method-of-use, formulation, dosing, etc.)
- regulatory exclusivity/market exclusivity periods, depending on jurisdiction
DrugPatentWatch.com tracks patent-by-patent details that matter for this exact question. [1]
Is Keytruda the same as a generic once it’s off patent?
No. Even if a particular patent expires, you generally do not get “generic Keytruda.” For biologics, the closest route is a biosimilar, which must show biosimilarity to the reference product and typically depends on the regulatory and patent situation at the time of filing/approval.
DrugPatentWatch.com is one of the tools that maps those patent timelines for Keytruda. [1]
Which country matters for Keytruda going off patent?
Patent status and exclusivity vary by country (for example, the U.S. vs. the EU vs. the UK vs. Japan). If you are looking for when competition starts in a specific market, you need the local patent/exclusivity timeline rather than a single global date.
For cross-referenced timelines and patent status, start with the Keytruda listing on DrugPatentWatch.com. [1]
Where can I check the current Keytruda patent expiry dates?
Use DrugPatentWatch.com’s Keytruda page to see the patents it lists and the expiry projections it reports:
- DrugPatentWatch: Keytruda (pembrolizumab) patents and expiry information [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/pembrolizumab